Eliem Therapeutics Inc Stock

$2.38

8.68%

Nasdaq, Aug 22, 10:00 pm CET

ISIN

US28658R1068

Symbol

CLYM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Eliem Therapeutics Inc Stock price

$2.38

-13.52 85.03% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.19 8.68%

ISIN

US28658R1068

Symbol

CLYM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$161.3m

Enterprise Value

$76.6m

Net debt

positive

Cash

$84.7m

Shares outstanding

67.8m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

0.9

Financial Health

Equity Ratio

97.6%

Return on Equity

-34.9%

ROCE

-28.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-52.9m | -

EBIT

$-53.0m | $-67.4m

Net Income

$-46.8m | $-51.3m

Free Cash Flow

$-39.7m

EPS

$-0.7

FCF per Share

$-0.6

Short interest

6.4%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Eliem Therapeutics Inc forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Eliem Therapeutics Inc forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	20 20	108% 108% -
- Research and Development Expense	33 33	444% 444% -
EBITDA	-53 -53	- -
- Depreciation and Amortization	0.04 0.04	- -
EBIT (Operating Income) EBIT	-53 -53	241% 241% -
Net Profit	-47 -47	27% 27% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Eliem Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

13 days ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies; Phase 1 Trial Expected to Initiate in the Coming Weeks, with ...

Neutral

GlobeNewsWire

●

3 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into em...

Neutral

GlobeNewsWire

●

3 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial P...

More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office	United States
CEO	Aoife Brennan
Founded	2018
Website	climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now